Jeppe Ragnar Andersen

Accelerating Drug Development with AI and Smart Imaging Superior Science and Risk-Sharing Business Models Cloud Platform DYNAMIKA for Central Data Management and Review Imaging Protocol Design and Optimal Endpoint Selection
Jeppe-135x135

Jeppe Ragnar Andersen

Investment Director
Global Clinical Research and Investments
Jeppe Ragnar Andersen is CEO of Nordic Bioscience, Denmark. Jeppe is actively doing research into clinical trial methodology with a special focus on implementing risk-based monitoring and cost-benefit optimization. Over the years, Jeppe has been involved on an operational and executive level in numerous clinical studies with more than 15,000 patients within the therapeutic fields of osteoporosis, osteoarthritis and diabetes. Jeppe brings operational expertise of running global multi-center clinical trials in MSK conditions.

Richard Barker, OBE

Accelerating Drug Development with AI and Smart Imaging Superior Science and Risk-Sharing Business Models Cloud Platform DYNAMIKA for Central Data Management and Review Imaging Protocol Design and Optimal Endpoint Selection
Richard_Barker-135x206

Richard Barker, OBE

Precision Medicine Expert
Prof. Barker's 25-year business career has spanned biopharmaceuticals, diagnostics and bioinformatics – both in the USA and EU, focused on accelerating the translation of therapeutics with the potential to improve healthy lifespan on a global scale. Richard is an expert in precision medicine, stratified medicine, translational partnerships between academia and industry. He headed the Association of the British Pharmaceutical Industry, currently on the boards of CelGene, New Medicine Partners, Centre for Advancing Sustainable Medical Innovation (CASMI), the UK government Precision Medicine Catapult and Honorary Fellow of the British Pharmacological Society.

Robert Karl

Accelerating Drug Development with AI and Smart Imaging Superior Science and Risk-Sharing Business Models Cloud Platform DYNAMIKA for Central Data Management and Review Imaging Protocol Design and Optimal Endpoint Selection
RobertKarl-MRI1-135x135

Robert Karl

Investment Director
Investment Strategy and Capital for Life-Sciences Companies
A partner of RBV Capital, Robert joint IAG in 2015 to contribute to strategic growth of the group and expand Bio-Partnering. He is heavily involved into building a diversified investment portfolio composed of early to market stage products. His interests are in biopharmaceuticals, biomedical technology and services, bioinformatics and healthcare IT, medical devices and innovative healthcare providers as well as cross-discipline companies.

Jeremy Nettle

Accelerating Drug Development with AI and Smart Imaging Superior Science and Risk-Sharing Business Models Cloud Platform DYNAMIKA for Central Data Management and Review Imaging Protocol Design and Optimal Endpoint Selection
Jeremy-Nettle-135x173

Jeremy Nettle

NED
Digital Disruption on the Healthcare Expert
Jeremy has served as a Global Client Adviser for Healthcare in Oracle for 10 years and joint IA-group to provide our clients with deep strategic insight into the use of cloud based next generation systems and analytics in clinical practise. Jeremy is a global expert on the impact of digital disruption on the healthcare market and the NHS. His key role is in providing clinical, change management and technology expertise to the life sciences companies, focused on digital transformation solutions to meet the requirement of a changing and demanding and integrated health science market across the UK and Europe.

Richard Nichol

Accelerating Drug Development with AI and Smart Imaging Superior Science and Risk-Sharing Business Models Cloud Platform DYNAMIKA for Central Data Management and Review Imaging Protocol Design and Optimal Endpoint Selection
Richard

Richard Nichol

Chief Finance Officer
Financial, P&L and Investment Professional with 20+ years of Expertise in Life science Industry
Successful and experienced hands-on Chief Financial Officer with board level experience of working in the pharmaceuticals (CRO), software and high tech industries. International, PE backed board level experience. Skilled in Statutory and Management Accounting, R&D Tax Credits, Corporate Governance, Strategic and Business Planning, Change Management and Facility Management (FM). FCCA qualified.

Michael Clark, PMP

Accelerating Drug Development with AI and Smart Imaging Superior Science and Risk-Sharing Business Models Cloud Platform DYNAMIKA for Central Data Management and Review Imaging Protocol Design and Optimal Endpoint Selection
MichaelClark

Michael Clark, PMP

Chief Operating Officer
Building Teams and Scalling Capabilities to Deliver Global Scale Imaging Clinical Trials
A Senior Clinical Director with extensive experience in undertaking strategic planning, oversight and execution of clinical programs and leading staff across multiple project areas globally. Skilled in needs assessment, quality assurance, managing programmes, communicating deadlines and completing projects within budget and on-time. Committed to achieving and exceeding targets in a drive to meet business objectives with strong clinical expertise and stakeholder management abilities.

Christophe Berthoux, MD

Accelerating Drug Development with AI and Smart Imaging Superior Science and Risk-Sharing Business Models Cloud Platform DYNAMIKA for Central Data Management and Review Imaging Protocol Design and Optimal Endpoint Selection
archimed-christophe-2_3

Christophe Berthoux, MD

Chairman
Biotech and Pharma Drug Development Strategy
Christophe is IAG's Chairman and an Operating Parter in ArchiMed, independent investment firm specialized in the Healthcare industries. Prior to this, he has spent his 20+ year career within the Clinical Research industry, and brings extensive expertise and knowdledge of this sector. Christophe was CEO of UK based Synexus, a leading global SMO and European CEO of Citoxlab Christophe Berthoux, is a doctor in veterinary medicine and holds an MBA from Purdue University, Indiana (US).

Jamshid Dehmeshki, PhD

Accelerating Drug Development with AI and Smart Imaging Superior Science and Risk-Sharing Business Models Cloud Platform DYNAMIKA for Central Data Management and Review Imaging Protocol Design and Optimal Endpoint Selection
JamshidPhoto

Jamshid Dehmeshki, PhD

Chief Technology Officer
Expert in Imaging, AI and Machine Learning in Drug Development
Prof. Jamshid Dehmeshki, CTO of IAG, is a software engineer with passion for medical imaging and 20+ years of mixed academic and commercial background. He is supporting IAG's bio-pharma clients in the design and delivery of complex imaging trials that require the best in breed technology solutions. Jamshid's experience is in enterprise development environments, medical device quality control, algorithm development and patenting novel approaches to medical image analysis. He is widely published academic and recognized speaker in the field of medical image analysis, data mining, algorithm development, medical image and video processing, mathematical, stochastic and forecasting modelling and numerical analysis. He has published more than 170 scientific research papers, five book chapters, and holds thirteen patents.

Dr. Jan Lundberg

Accelerating Drug Development with AI and Smart Imaging Superior Science and Risk-Sharing Business Models Cloud Platform DYNAMIKA for Central Data Management and Review Imaging Protocol Design and Optimal Endpoint Selection
Jan Lundberg_TB Alliance Board of Directors

Dr. Jan Lundberg

Chair of Scientifc Advisory Board
Novel Drug Discovery and Development
Jan joined IAG in 2018 to chair IAG’s distinguished board of in-house scientists, imaging experts and academic collaborators and closely work with biotech and pharma partners. Jan's expertise and many years of experience are in the critical assessment of novel therapeutic agents and strategic positioning to maximize the chances of their success. Dr. Lundberg, a scientist with over 22 years of experience in global pharmaceutical R&D. Until recently he was heading R&D organization for Ely Lilly and previously – global research for AstraZeneca. He was involved with discovery of more than 200 candidate drugs and 22 approved products across multiple therapeutic areas, including immunology, oncology and neurology; he has been instrumental for the use of imaging cross therapeutic area projects including amyloid and tau PET imaging in Alzheimer’s dementia. His career began in Karolinska institutet, where he was a professor of pharmacology and a co-founder of Aerocrine AB.

Dr. Olga Kubassova, PhD

Accelerating Drug Development with AI and Smart Imaging Superior Science and Risk-Sharing Business Models Cloud Platform DYNAMIKA for Central Data Management and Review Imaging Protocol Design and Optimal Endpoint Selection
olga_new_team

Dr. Olga Kubassova, PhD

Chief Executive Officer
Life Science Innovator, Venture Partner and Bio-Pharma Drug Development Strategist
CEO of IAG and life science innovator, mathematician with expertise in actively managing innovation in life science companies, asset positioning, and strategy. Extensive expertise and domain knowledge in identifying innovative approaches to clinical research, disruptive technology platforms and novel therapeutics. Olga is an active researcher, with over 80 publications, books and book chapters. She is a scientific adviser to the UK government and EU funding bodies. Her ambition is to bring truly disruptive technologies, artificial intelligence and best of machine learning to clinical practice and research, while expanding IAG's footprint and partnerships.